Phospho-Chk1 (Ser280) Antibody from MYBIOSOURCE INC.

Search, find, compare suppliers for anti-Phospho-Chk1 (Ser280) antibody, protein, ELISA kits.

Edit 
Antigenic SpecificityPhospho-Chk1 (Ser280)
Clonepolyclonal
Host SpeciesRabbit
Reactive Specieshuman
Isotypen/a
Formatimmunogen affinity purified
Size0.1 mL
Concentrationn/a
ApplicationsWestern Blot (WB); ELISA (EIA)
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionPolyclonal antibody to detect endogenous levels of Chk1 (pS280) in human samples. Serine/threonine-protein kinase which is required for checkpoint-mediated cell cycle arrest and activation of DNA repair in response to the presence of DNA damage or unreplicated DNA. May also negatively regulate cell cycle progression during unperturbed cell cycles. This regulation is achieved by a number of mechanisms that together help to preserve the integrity of the genome. Recognizes the substrate consensus sequence [R-X-X-S/T]. Binds to and phosphorylates CDC25A; CDC25B and CDC25C. Phosphorylation of CDC25A at 'Ser-178' and 'Thr-507' and phosphorylation of CDC25C at 'Ser-216' creates binding sites for 14-3-3 proteins which inhibit CDC25A and CDC25C.
ImmunogenImmunogen: Synthesized peptide derived from human Chk1 around the phosphorylation site of S280
Other Names[Serine/threonine-protein kinase Chk1; CHK1 checkpoint homolog; Cell cycle checkpoint kinase; Checkpoint kinase-1; CHEK1; CHK1], [CHEK1]
Gene, Accession #[Chk1], Gene ID: 1111, NCBI: NP_001107593.1, UniProt: O14757
Catalog #MBS846140
Price$335
Order / More InfoPhospho-Chk1 (Ser280) Antibody from MYBIOSOURCE INC.
Product Specific Referencesn/a
MYBIOSOURCE INC.
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166

sales@mybiosource.com

http://www.MyBioSource.com

Profile of MYBIOSOURCE INC.
Return to Antibodies

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.